ǂa ǂreport from the real-life series of high-grade B-cell lymphomas treated with different therapeutic protocols at the Institute of Oncology Ljubljana
Lučka Boltežar (Author), Samo Rožman (Author), Gorana Gašljević (Author), Biljana Grčar-Kuzmanov (Author), Barbara Jezeršek Novaković (Author)

Abstract

High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are known for their aggressive clinical course and so are the ones with MYC and BCL2 protein overexpression. The optimal therapy for these lymphomas remains to be elucidated. A retrospective analysis of all diffuse large B-cell lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements diagnosed between 2017 and 2021 at the Institute of Oncology Ljubljana, Slovenia, has been performed. Only patients with double-expressor lymphoma (DEL), double-hit lymphoma (DHL), or triple-hit lymphoma (THL) were included. Demographic and clinical parameters were assessed, as well as progression-free survival (PFS) and overall survival (OS). In total, 161 cases out of 309 (161/309; 52,1%) were classified as DEL. Sixteen patients had DHL, MYC/BCL2 rearrangement was observed in eleven patients, and MYC/BCL6 rearrangement was observed in five patients. Five patients were diagnosed with THL. Out of 154 patients (according to inclusion/exclusion criteria) included in further evaluation, one-hundred and thirty-five patients had double-expressor lymphoma (DEL), sixteen patients had DHL, and three patients had THL. In total, 169 patients were treated with R-CHOP, 10 with R-CHOP and intermediate-dose methotrexate, 19 with R-DA-EPOCH, and 16 with other regimens. The median follow-up was 22 months. The 5-year OS for the whole DEL group was 57.1% (95% CI 45.9–68.3%) and the 5-year PFS was 76.5% (95% CI 72.6–80.4%). The log-rank test disclosed no differences in survival between treatment groups (p = 0.712) while the high-risk international prognostic index (IPI) carried a significantly higher risk of death (HR 7.68, 95% CI 2.32–25.49, p = 0.001). The 5-year OS for DHL patients was 32.4% (95% CI 16.6–48.2%) while all three TH patients were deceased or lost to follow-up. Our analyses of real-life data disclose that the R-CHOP protocol with CNS prophylaxis is a successful and curative treatment for a substantial proportion of DEL patients.

Keywords

limfomi;dvojno izražen limfom;onkologija;lymphoma;double-expressor lymphoma;oncology;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Organization: OI - Institute of Oncology
Publisher: MDPI
UDC: 616.4
COBISS: 183791619 Link will open in a new window
ISSN: 2227-9059
Views: 88
Downloads: 33
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: limfomi;dvojno izražen limfom;onkologija;
Source comment: Nasl. z nasl. zaslona; Opis vira z dne 5. 2. 2024;
Pages: str. 275-1-275-13
Volume: ǂVol. ǂ12
Issue: ǂno. ǂ2
Chronology: 2024
DOI: 10.3390/biomedicines12020275
ID: 23467886
Recommended works:
, ǂa ǂreport from the real-life series of high-grade B-cell lymphomas treated with different therapeutic protocols at the Institute of Oncology Ljubljana
, proceedings
, no subtitle data available
, no subtitle data available
, no subtitle data available